Engineered t cells target hidden leukemia cells in new trial
NCT ID NCT07645469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a protein called WT1 found on leukemia cells, combined with the chemotherapy drug azacitidine. The goal is to find a safe dose and see if this approach can help the immune system clear the remaining cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FH-WT1-E50 TCR T cells and azacitidine
What this could lead to
If successful, this approach could offer a new way to eliminate remaining leukemia cells in patients with minimal residual disease, potentially preventing relapse.
What could go wrong
This is an early phase I trial with only 9 participants, so safety and dosing are still being established. The treatment may cause severe side effects or may not effectively control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••